HTGF backs Thermosome's €4.6m round

The proceeds from the first financing round and the grant will be used to move Thermosome's lead candidate through good manufacturing practice and pre-clinical development into a first clinical study.

Thermosome hopes to use its novel platform technology to enlarge the therapeutic index and safety window of drugs and reach improved therapeutic outcomes in patients.

Bayern Kapital was founded on the initiative of the Bavarian government in 1995 as a subsidiary of the Bavarian LfA Foerderbank. It provides equity capital financing for the founders of young, innovative technology companies in Bavaria. It manages 11 investment funds with a total volume of around €340m and has invested almost €210m in 230 companies.

Company
Founded in 2010 and based in Munich, Thermosome's TSL technology is a proprietary drug delivery platform used to create thermosensitive drug-loaded nanocarriers which locally release their encapsulated drug within the blood stream upon the influence of mild heat.

The firm's technology was invented at the Max Planck Institute for Biophysical Chemistry in Goettingen and is being further developed at the University Hospital of the Ludwig-Maximilians-Universitaet Munich.

People
Thermosome - Pascal Schweizer (managing director).
Bayern Kapital - Monika Steger (investment director).
High-Tech Gründerfonds - Caroline Fichtner (investment director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Germany